<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20220526054993N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-06-29</date_registration>
      <primary_sponsor>Alborz University of Medical Science</primary_sponsor>
      <public_title>Evaluation of the effect of intra-articular injection of dexamethasone and vitamin D compared to injection of dexamethasone alone on signs of knee osteoarthritis</public_title>
      <acronym></acronym>
      <scientific_title>The Effects of Intra-articular injection of dexamethasone and vitamin D compared to injection of just dexamethasone on signs of knee osteoarthritis with grade 2 and 3_ a randomized double-blind clinical trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-08-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>154</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/63833</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Random allocation of patients to case and control groups is done using "permuted balance block randomization technique" with a ratio of (1: 1).
The blocks considered in this study include 4 patients, Blinding description: For the two-sided blindness of the study, after randomly assigning the patient to one of the two groups, one of the colleagues fills the syringe from one of the two types of vial that both have the same color.
(Vitamin D and dexamethasone or dexamethasone alone).
Both the physician and the patient are not informed of the contents of the syringe.</study_design>
      <phase>3</phase>
      <hc_freetext>Knee osteoarthritis with grade 2 and 3.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: After randomization , 4 mg of dexamethasone plus one hundred and fifty thousand international units (IU) of vitamin D3 will be injected into the intra-articular space of the patient's knees separately (right and left knee). The pharmacological form of vitamin D3 which we use is Cholecalciferol from AburaihanCo.Iran . Intervention 2: Control group: After randomization, 4 mg of dexamethasone is injected separately into the intra-articular space of the knees of control patients separately (right knee and left knee). To double-blinding, the drug is injected in the same condition as the intervention group.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All data will be available after deidentification

When:
Upon rational request

To whom:
To the researchers

Conditions:
For research purposes, such as meta analysis or systematic reviews

Where to obtain:
From corresponding author

How to obtain:
To be an verified researcher in the field

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Arvin Najafi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shahid Madani Square, Mahan Boulevard, Taleghani intersection, Kara</address>
        <city>Karaj</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3143744693</zip>
        <telephone>+98 26 3442 7001</telephone>
        <email>parsmedicine@gmail.com</email>
        <affiliation>Alborz University of Medical Science</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Arvin Najafi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shahid Madani Square, Mahan Boulevard, Taleghani intersection, Kara</address>
        <city>Karaj</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3143744693</zip>
        <telephone>+98 26 3442 7001</telephone>
        <email>parsmedicine@gmail.com</email>
        <affiliation>Alborz University of Medical Science</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Age between 40 to 65
Bilateral knee osteoarthritis
Having score 2 and 3 of KL system radiography
Completion of informed consent form to enter the study</inclusion_criteria>
      <agemin>40 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Presence of secondary cause for knee osteoarthritis
Allergic history to dexamethasone or vitamin D
History of diabetes or coagulopathy
History or manifestation of joint infection or deformity</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>M16.30</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: After randomization , 4 mg of dexamethasone plus one hundred and fifty thousand international units (IU) of vitamin D3 will be injected into the intra-articular space of the patient's knees separately (right and left knee). The pharmacological form of vitamin D3 which we use is Cholecalciferol from AburaihanCo.Iran .</i_keyword>
      <i_keyword>Control group: After randomization, 4 mg of dexamethasone is injected separately into the intra-articular space of the knees of control patients separately (right knee and left knee). To double-blinding, the drug is injected in the same condition as the intervention group.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>The score obtained in the WOMAC knee score to evaluate the degree of osteoarthritis. Timepoint: Before intervention and 1, 3, and 6 month after intervention. Method of measurement: WOMAC knee score.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>The amount of analgesic consumption. Timepoint: Before intervention and 1, 3, and 6 mouths after intervention. Method of measurement: Questionnaire to assess the number of analgesics consumed per week.</sec_outcome>
      <sec_outcome>Range of motion of the knee. Timepoint: Before intervention and 1, 3, and 6 mouths after intervention. Method of measurement: Clinical examination.</sec_outcome>
      <sec_outcome>Joint pain. Timepoint: Before intervention and 1, 3, and 6 mouths after intervention. Method of measurement: The size of joint pain in millimeters on the scaled ruler.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Alborz University of Medical Science</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-04-16</approval_date>
        <contact_name>Research Ethics committee of Alborz University of Medical Science</contact_name>
        <contact_address>N.528 - 120 street - Eram boulvard - Mehrshahr - Karaj Karaj Alborz Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
